Mast cell activation syndrome (MCAS)

What changes during this transition

Mast Cell Activation Syndrome (MCAS) is a clinical syndrome — not a single disease — defined by episodic release of mast cell mediators (tryptase, histamine, prostaglandin D2, leukotriene E4) producing multisystem symptoms across skin (flushing, urticaria, pruritus, angioedema), GI (cramping, diarrhea, nausea), cardiovascular (presyncope, tachycardia, hypotension), and neuropsychiatric (brain fog, anxiety, headache) domains, often triggered by foods, medications, temperature changes, mechanical stimuli, or stress. The diagnostic framework is genuinely contested. The Valent et al. (2007/2012) Consensus-1 criteria are strict: episodic symptoms in 2 or more organ systems, documented serum tryptase elevation >20% above individual baseline + 2 ng/mL within 4 hours of an episode, and clinical response to mast cell-targeted therapy. The Akin/Castells/Afrin Consensus-2 framework is broader, accepting 24-hour urinary mediator elevations (N-methylhistamine, prostaglandin D2 metabolite, leukotriene E4) as alternative biochemical evidence. Hereditary alpha-tryptasemia (HαT) — TPSAB1 alpha-tryptase copy number elevation, affecting roughly 5-7% of the general population — is a load-bearing confounder. HαT raises baseline tryptase above the conventional 8 ng/mL threshold without indicating clonal disease, and it co-occurs with MCAS-like symptoms in a meaningful subset. Tryptase genetic testing has become part of the appropriate diagnostic workup for that reason. MCAS must also be distinguished from systemic mastocytosis (clonal proliferation driven by the KIT D816V mutation, requiring bone marrow biopsy + serum tryptase + KIT mutation testing). Avapritinib (Ayvakit/Ayvakyt, BLU-285), a selective KIT D816V inhibitor, received FDA approval for advanced systemic mastocytosis in June 2021 and indolent systemic mastocytosis in January 2023 on the strength of the PIONEER and HARBOR trials. Bezuclastinib (Cogent Biosciences) is in Phase 3 SUMMIT. These KIT D816V inhibitors are NOT MCAS treatments — MCAS by definition is non-clonal — but they're often confused in patient communities. The MCAS standard of care is layered. Trigger identification and avoidance comes first. First-line pharmacotherapy is non-sedating H1 antihistamines (cetirizine, fexofenadine, loratadine, often at doses higher than over-the-counter labeling) plus H2 antihistamines (famotidine). Mast cell stabilizers — oral cromolyn sodium for GI symptoms, ketotifen where available — are added next. Leukotriene receptor antagonists (montelukast, zafirlukast) target the leukotriene arm. Aspirin can help prostaglandin-mediated symptoms but can also trigger and is approached cautiously. Omalizumab (anti-IgE monoclonal) is increasingly used off-label with emerging evidence. IVIG has small-series support for refractory cases. Throughout all of this, epinephrine auto-injector availability and a written emergency action plan are non-negotiable — MCAS patients can have anaphylactic episodes. The mast cell triad — MCAS + POTS (postural orthostatic tachycardia syndrome / dysautonomia) + hEDS (hypermobile Ehlers-Danlos syndrome) — is the third clinical reality this substrate acknowledges. The three conditions co-occur far more often than chance, and the symptom domains overlap heavily: brain fog, fatigue, cardiovascular instability, and connective-tissue complaints map across all three. No peptide in the Juno library has MCAS clinical trial data. BPC-157's community 'mast cell stabilization' framing extrapolates from rodent gastric injury models. KPV has real mucocutaneous anti-inflammatory mechanism via α-MSH/NF-κB but no MCAS-specific evidence. Thymosin alpha-1's hepatitis-B-registered T-cell maturation case doesn't propagate to MCAS under Rule 6. LL-37 is the sharpest contraindication in the substrate: it's a known MRGPRX2 agonist, the same non-IgE receptor responsible for several drug-induced pseudoallergic reactions, and degranulates human mast cells directly in published assays — adding it to an MCAS regimen is mechanically opposed to what cromolyn, montelukast, and omalizumab are trying to do. NMN doesn't have an MCAS case at all; it shows up because general-aging supplement stacks travel with patients into their conditions.